Objective: Autologous stem cell transplantation is an important strategy for patients with relapsed or refractory lymphoma. Although various regimens for peripheral blood stem cell collection have been used, the optimal regimen has not yet been established. We aimed to evaluate the mobilization efficacy and safety of the regimen consisted of etoposide and cytarabine (EC regimen). Results: The median age of the patients was 55 years. The most common underlying diseases were diffuse large B-cell lymphoma (46%) and follicular lymphoma (26%). Three-quarters of patients were in their second complete or partial remission. The median total number of collected CD34 + cells was 10.6 × 10 6 kg -1 . Forty-two patients (91%) yielded at least 2 × 10 6 kg -1 CD34 + cells within a median of 2 apheresis days, and 33 patients (72%) achieved it with only one apheresis. Successful mobilization was observed in five of six patients who failed to mobilize previously. Although febrile neutropenia occurred in 22 patients (48%), no fatal infection was observed. Conclusion: The EC regimen was highly effective in lymphoma patients, including patients who mobilized poorly with other regimens.
Introduction
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a well-established therapeutic strategy for patients with relapsed or refractory lymphoma (1) (2) (3) . For successful ASCT, collection of an adequate number of peripheral blood stem cells (PBSCs) is essential (4, 5) . Procedures to collect PBSCs are grouped into two major categories: cytokine mobilization using granulocytecolony stimulating factor (G-CSF) alone and chemomobilization using chemotherapy followed by G-CSF administration (6) . For patients with lymphoma, a chemomobilization strategy is generally adapted, and several regimens, such as high-dose cyclophosphamide, DHAP (dexamethasone, high-dose cytarabine, cisplatin), ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin), ICE (ifosfamide, carboplatin, etoposide) and CHASE (cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide), are used (7) (8) (9) (10) (11) (12) (13) . However, approximately 10% of patients experience mobilization failure (14) .
In such patients, it has been reported that the use of G-CSF plus highdose etoposide or cytarabine is sometimes effective (15) (16) (17) .
At our institute, we have used a regimen consisted of etoposide and cytarabine (EC regimen) for mobilization in lymphoma patients since the 1990s and have experienced good mobilization efficacy. Here, we report our experiences of mobilization with the EC regimen over ten years.
Patients and methods

Patients
This retrospective observational study included 46 patients with lymphoma who had undergone PBSC harvest (PBSCH) following the EC regimen at Toyohashi Municipal Hospital from January 2004 to December 2013. Inclusion criteria for PBSCH were patients beyond the first complete remission (CR), those with refractory disease, or those in first CR or partial remission (PR) with risk factors of relapse, such as patients with a high international prognostic index (IPI) score. In refractory or relapsed patients, the EC mobilization was performed after two or three cycles of salvage chemotherapy. This retrospective study was approved by the institutional review board of Toyohashi Municipal Hospital, and written informed consent for the protocol was obtained from all patients.
Stem cell mobilization with the EC regimen
The EC regimen consisted of etoposide (100 mg/m 2 /day) infused continuously on days 1 to 4 and cytarabine (100 mg/m 2 /day) also infused continuously on days 1 to 4. Rituximab (375 mg/m 2 ) was administered in patients with B-cell lymphoma on the day before the EC regimen. G-CSF (10 μg/kg s.c.) was initiated in the neutropenic phase and continued until the end of leukapheresis. Leukapheresis was initiated on the day, when the WBC count was found to be more than 5 × 10 9 l -1 using a FRESENIUS AS104 blood cell separator (Fresenius, St. Wendel, Germany). Number of CD34 + cell was measured at SRL, Inc. (Tokyo, Japan) using flow cytometry (18 ), days from chemotherapy to apheresis (<17 days vs. ≥17 days), red blood cell transfusion (required vs. not required), platelet transfusion (<40 units vs. ≥40 units) and previous history of mobilization failure (yes vs. no). Variables with a P-value <0.1 in the univariate analysis were entered into the multivariate analysis. All tests were twosided, and P-value <0.05 was considered significant.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . The median age was 55 years old, and approximately the same numbers of male and 
34 (74) Beyond 3 (7) Salvage regimen, n (%) EPOCH 22 (48) Bendamustine 8 (17) CHASE 6 (13) Hyper-CVAD/MA 6 (13) Others 4 (9) Previous failed mobilization, n (%) 6 (13) DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PCNSL, primary central nervous system lymphoma; MALT, mucosa-associated lymphoid tissue; PMBL, primary mediastinal large B-cell lymphoma; LPL/WM, lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia; AITL, angioimmunoblastic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; ALCL, anaplastic large cell lymphoma; HL, Hodgkin lymphoma; CR, complete remission; PR, partial remission. 11 (24) Successful collection, n (%) 42 (91) Good mobilizers, n (%) 33 (72) (successful collection on the first day of apheresis) Failed collection, n (%) 4 (9) female patients were included. Underlying diseases were DLBCL (46%), follicular lymphoma (FL) (26%), mantle cell lymphoma (MCL) (7%) and others. Most patients were in their CR1/PR1 or CR2/PR2 at mobilization. Patients who underwent PBSCH in CR1/ PR1 included DLBCL with high IPI score (n = 2), MCL (n = 2), Waldenstrom's macroglobulinemia (n = 1), primary central nervous system lymphoma (n = 1), primary mediastinal large B-cell lymphoma (n = 1), angioimmunoblastic T-cell lymphoma (n = 1) and enteropathy-associated T-cell lymphoma (n = 1). Twenty-two patients (48%) received the EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride) as the salvage regimen. Six patients who had experienced prior mobilization failure with other regimens were included.
Mobilization efficacy
The EC mobilization resulted in successful collection (>2 × 10 6 kg -1 CD34 + cells) in 91.3% of patients within a median of two apheresis (Table 2 ). Furthermore, 72% of patients were good mobilizers. The first day of apheresis was at a median of day 16 after the administration of the EC regimen. The median number of CD34 + cells collected in the first day of apheresis was 4.5 × 10 6 kg -1 , and a total of 10.6 × 10 6 kg -1 were collected (Fig. 1 ).
Patients who failed previous PBSCH
The mobilization efficacy of the EC regimen in patients who previously failed PBSCH is summarized in Table 3 . Five of the six patients (83%) yielded more than 2 × 10 6 kg -1 CD34 + cells in one to three apheresis. One patient who failed even with the EC regimen had a history of fludarabine administration.
Safety
Grade 4 neutropenia was observed in 46 patients (98%), and G-CSF was started at a median of day 9. As a result, 22 patients (48%) developed grade 3 febrile neutropenia. Grade 4 thrombocytopenia was observed in 39 patients (83%), and 43 patients (94%) received platelet transfusions. Red blood cell transfusions were also required in 22 patients (48%). Only two patients developed grade 3 nonhematological adverse events (one vitreous hemorrhage and one hypokalemia). No grade 4 adverse events or treatment-related deaths were observed (Table 4) .
Factors associated with good mobilizers
Finally, we investigated the clinical characteristics of good mobilizers (Table 5) . Good mobilizers received EPOCH or bendamustine more frequently as the salvage regimen, fewer transfusion, and PBSCH at shorter interval from chemotherapy than poor mobilizers. In addition, fewer patients who had experienced previous mobilization failure were included in good mobilizers. In the multivariate analysis, EPOCH or bendamustine for the salvage regimen, no red blood transfusion and earlier initiation of apheresis were identified as significant predicting factors for good mobilizers (Table 6 ). Although inexperience of previous mobilization failure was a significant factor in univariate analysis, it was not associated with good mobilizers in multivariate analysis.
Discussion
This study demonstrated the high success rate of apheresis (91.3%) with the EC regimen in lymphoma patients. Other regimens, such as ICE, ESHAP and DHAP have also been reported to be effective for apheresis in approximately 90% of patients (8, 11) . However, these reports did not always discuss the number of apheresis. The remarkable finding regarding the EC regimen was that sufficient CD34 + cells were collected within only one apheresis in 72% of patients. This can contribute to a reduction in the physical burden to patients and costs for apheresis, which are quite important factors in clinical settings. In addition, the EC regimen was also effective in the patients who previously failed PBSC collection with other regimens. Regimens including high-dose etoposide or high-dose cytarabine have been reported to be effective in patients who have previously failed mobilization (15) (16) (17) 20, 21) . Although the EC regimen did not include either high-dose etoposide or high-dose cytarabine, it was sufficient for successful collection. It should be mentioned that the presence or absence of previous mobilization failure was not associated with mobilization efficacy in multivariate analysis. The combination therapy enabled us to give lower doses of each drug to the patients. Reduction of etoposide might contribute to reducing the risk of secondary malignancies, and avoidance of high-dose cytarabine could eliminate adverse events such as cerebellar toxicity. Considering these factors, the combination of cytarabine and etoposide may be a choice for patients who have experienced mobilization failure or who are at a high risk of poor mobilization.
In our cohort, about a half of patients received EPOCH as the salvage regimen, and most of them received CHOP (prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride) regimen as the primary treatment. Therefore, they were given around 400-500 mg/m 2 of doxorubicin before stem cell mobilization. It is preferable to avoid additional doxorubicin for such patients to reduce the risk of anthracyclineinduced cardiomyopathy. These safety concerns in addition to the high The type of salvage regimen affected the PBSC yields in this study, and the EPOCH or bendamustine regimen was associated with good mobilizers. The hyper-CVAD/MA regimen has been reported to be a risk factor for reduced PBSC yields in patients with mantle cell lymphoma, which is consistent with our results (22) . Other factors associated with good mobilizers were earlier hematological recovery and lesser transfusion, which might be related to the hematological toxicity of prior chemotherapy. Mild toxicity for hematopoietic stem cells might be associated with favorable PBSC yields in patients who received the EPOCH or bendamustine regimens.
Hematological toxicity was relatively severe in the EC regimen. The incidence of febrile neutropenia in patients who received the EC regimen (48%) was higher than other mobilization regimens such as ESHAP (5-18%), DHAP and ICE (16%) (8) (9) (10) . From this aspect, the use of the EC regimen needs particular attention for patients who are susceptible to severe infection such as patients with focus of infection. On the other hand, patients who are at high risk of mobilization failure or those with the history of mobilization failure can be the best candidate for this regimen considering its high success rate and efficacy in patients who previously experienced mobilization failure. Although febrile neutropenia was observed frequently in this study, it could be easily managed by usual antibiotic administration. Other non-hematological severe adverse events were rarely observed; therefore, the toxicity of the EC regimen was acceptable on the whole.
In summary, we retrospectively assessed the efficacy and safety of the EC regimen. It had a high success rate of apheresis, even in poor mobilizers with other regimens, and its toxicity was tolerable. This regimen can be a choice for chemomobilization for lymphoma patients, especially those with a risk factor for mobilization failure. 
